表紙
企業レポート

PharmaPoint:前立腺癌−−現在・将来の市場参入企業

PharmaPoint: Prostate Cancer - Current and Future Players

発行 GlobalData 商品コード 263601
出版日 ページ情報 英文 57 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
PharmaPoint:前立腺癌−−現在・将来の市場参入企業 PharmaPoint: Prostate Cancer - Current and Future Players
出版日: 2012年12月31日 ページ情報: 英文 57 Pages
概要

当レポートでは、世界の前立腺がん関連市場における既存企業および新規参入企業について分析し、市場全体の将来展望や促進・抑制要因、現在・将来の競争動向、主要企業のプロファイル(企業概要、事業展開、財務状況、SWOT分析)、市場全体と各企業の将来展望などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進・阻害要因:世界市場の課題

第4章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • AstraZeneca
    • Abbott
    • Sanofi
    • Johnson & Johnson
    • Astellas Pharma

第5章 付録

図表一覧

目次
Product Code: GDHC1003FPR

Abstract

Summary

GlobalData has released its pharma report, "PharmaPoint: Prostate Cancer - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prostate Cancer Market. The report identifies and analyses the key companies shaping and driving the global Prostate Cancer market. The report provides insight into the competitive Prostate Cancer landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Prostate Cancer
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Prostate Cancer sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Prostate Cancer Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Prostate Cancer market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3 Company Profiles
    • 4.3.1. AstraZeneca
    • 4.3.2. Abbott
    • 4.3.3. Sanofi
    • 4.3.4. Johnson & Johnson
    • 4.3.5. Astellas Pharma

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Number of Prostate Cancer Patients Currently Seeking Treatment
    • 5.4.2. Percent Drug-treated Patients
    • 5.4.3. Percent Hormone Therapy-Treated Patients
    • 5.4.4. Drugs Included in Each Therapeutic Class
    • 5.4.5. Launch, Patent and Market Exclusivity Expiry Dates
    • 5.4.6. General Pricing Assumptions
    • 5.4.7. Individual Drug Assumptions
    • 5.4.8. Generic Erosion
    • 5.4.9. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in This Study
  • 5.6. Survey of Prescribing Physicians
  • 5.7. About the Authors
    • 5.7.1. Authors
    • 5.7.2. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Contact Us
  • 5.10. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Prostate Cancer, 2012-2022
  • Table 2: Global Prostate Cancer Market - Drivers and Barriers, 2012
  • Table 3: Key Companies in the Prostate Cancer, 2012
  • Table 4: AstraZeneca's Prostate Cancer Portfolio Assessment, 2012
  • Table 5: AstraZeneca's Prostate Cancer Portfolio SWOT Analysis, 2012
  • Table 6: Abbott's Prostate Cancer Portfolio Assessment, 2012
  • Table 7: Abbott's Prostate Cancer Portfolio SWOT Analysis, 2012
  • Table 8: Sanofi's Prostate Cancer Portfolio Assessment, 2012
  • Table 9: Sanofi's Prostate Cancer Portfolio SWOT Analysis, 2012
  • Table 10: J&J's Prostate Cancer Portfolio Assessment, 2012
  • Table 11: J&J's Prostate Cancer Portfolio SWOT Analysis, 2012
  • Table 12: Astellas Pharma's Prostate Cancer Portfolio Assessment, 2012
  • Table 13: Astellas Pharma's Prostate Cancer Portfolio SWOT Analysis, 2012
  • Table 14: Key Launch Dates
  • Table 15: Key Patent Expiries and Market Exclusivity Expiries
  • Table 16: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Prostate Cancer by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in Prostate Cancer, 2012-2022
Back to Top